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Philadelphia Drug Monitoring Program and Compliance with Department of Health Requirements
Paniz Heidari DO, William Wieczorek MD, Jayassree Iyer MD, Denise Pineda-Fortin MD, Elizabeth Liveright, MD
Thomas Jefferson Department of Obstetrics and Gynecology

Introduction
Opioid prescribing and deaths in the United States have increased
exponentially in the last several decades. As of 2011, the American Academy of
Pain Medicine and the Institute of Pain Medicine, estimate there are 100 million
people with chronic pain. This is more than cancer, diabetes and heart disease
combined. The CDC reports that in 2012 there were 41,502 deaths due to drug
poisoning (often referred to as drug-overdose deaths) in the United States, of
which 16,007 involved opioid analgesics.
In the zeal to treat pain as the fifth vital sign, we are now realizing that
patients have not been appropriately treated for their pain. Opiods have been a
mainstay in the treatment of acute pain, cancer, and palliative care. However, a
recent paradigm shift over the last several years has seen a surge in treatment of
chronic non-cancer pain with narcotics. Chronic non-cancer pain (CNCP) causes
significant morbidity, interfering with a patient’s ability to perform activities of
daily living, family life, and employment and is associated with significant
psychological stress.
While several states have already instituted a prescription drug monitoring
program(PDMP), legislation passed on Jaunary 1, 2017 in the the states of
Pennsylvania mandating physicians screen patients prior to prescribing narcotics
and other Schedule II –V drugs. This epidemic has left us posing a critical
question—how can we screen patients and monitor their prescription habits.

Objectives
With this newly instituted mandate, we found that many of the resident did
not have access to the PDMP query site. Our initial goal is to have 100% of
residents have log-in access to the PDMP site. Our long-term goals involve
increasing the query of the PDMP website by OB-GYN residents prior to
prescribing narcotic pain medication.
There are several changes that we can make to result in improvement of our
initial goal including: identifying residents that require access, working with
program coordinator to identify gaps in their PDMP application, and assisting in
providing DOH with any additional documentation necessary for access.
We will measure our improvement with a survey of residents as to their
ability to access the PDMP website prior to our intervention and afterwards.
After the intervention we wish to survey the residents on their use and utilization
of the Pennsylvania Department of Health Drug Prescription Drug Monitoring
Program

Results

Discussion
From May 8-18, 2017, the obstetrics and gynecology residents at Thomas
Jefferson University were surveyed on their views and compliance of the
Philadelphia Drug Monitoring Program. Out of the 29 residents in the program,
28 residents responded to the survey. The survey consisted of 12 questions
addressing a variety of views and compliance questions. Of the residents that
responded to the survey, 29% have their own access to the database and every
class has more than 50% of their class without access. 95% of residents have
attempted to gain access without success. Some statements that prevented
completing the process included a cumbersome process, denial of registration,
and the system “not working.” More than 50% of residents never query the
database when prescribing their narcotic, regardless of whether they have access
or use another person’s login. Of those residents that have access, 89% use the
system to query patients. Despite these statistics, 75% of residents feel that the
database is a useful tool for preventing prescription abuse and 77% feel that
querying the database changes their counseling of the patient. 100 % of residents
indicated they would offer providing personal information in order to receive
assistance in obtaining access.

Conclusion
Opioid pain medications remain a mainstay of CNCP treatment, but the
number of overdoses or deaths due to these medications continues to climb. A
multimodal approach must be utilized to address this crisis, including a more
complete understanding of individual prescriber habits and the sources of
patient’s narcotic prescriptions. Prescription drug monitoring programs aim to
curtail these injuries by allowing prescribers to see individual patient’s narcotic
history, altering their counseling or prescription choices based on the results of
the system query.
Our survey of OBGYN residents at a large, urban, academic hospital has
demonstrated that utilization of the PDMP is severely limited by resident
physician access to the PDMP. Interestingly, while residents predominantly
agreed that PDMP queries were useful for preventing abuse, more than half of
respondents indicated that they never query the database. Developing
department-wide PDMP registration programs and further integration of the
PDMP database into the existing EMR may increase utilization by increasing
ease of access.
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